Revalia Bio

Executive Summary

Revalia Bio is a pre-clinical biotechnology company pioneering a novel drug development approach termed 'Human Data Trials.' The company integrates a network of donated, perfused human organs to generate high-fidelity, clinically relevant data on drug safety, efficacy, and mechanism of action before traditional clinical trials commence. This platform aims to de-risk and accelerate R&D in oncology and immunology by providing human-relevant data early, potentially reducing failure rates and development timelines. Founded in 2020 and headquartered in Cambridge, MA, Revalia Bio operates at the intersection of advanced organ perfusion and drug development, targeting areas with high unmet need.

Upcoming Catalysts (preview)

• Q2 2026Lead candidate selection and preclinical proof-of-concept data for an oncology program40% success
• Q3 2026Series A financing or strategic partnership to support platform expansion50% success
• Q1 2027IND filing for first-in-human trial using Human Data Trials platform30% success